Defining the Standard of Care for High-grade Glioma - a NICE Deal for Patients

Clinical Oncology

Volumn 20, Issue 1, 2008, Pages 97-98

  Taylor, R E ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE;

ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DNA METHYLATION; DRUG CHOICE; DRUG EFFICACY; DRUG TARGETING; GLIOMA; HUMAN; LETTER; METASTASIS POTENTIAL; MORBIDITY; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; SURVIVAL TIME; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; GLIOBLASTOMA; HUMANS;

EID: 38149067492     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.09.011     Document Type: Letter

References (6)

1. Khanduri S., and Gerrard G. Defining the standard of care for high-grade glioma - a NICE deal for patients. Clin Oncol 19 (2007) 507-508
2. National Institute for Health and Clinical Excellence. Glioma (newly diagnosed and high-grade) - carmustine implants and temozolomide. Technology appraisal 2007.
3. Stupp R., Mason W.P., Bent M.J., et al., On behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy and concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
4. Davies E., Clarke C., and Hopkins A. Malignant cerebral glioma - I: survival, disability and morbidity after radiotherapy. Br Med J 313 (1996) 1507-1512
5. Davies E., Clarke C., and Hopkins A. Malignant cerebral glioma - II: perspectives of patients and relatives on the value of radiotherapy. Br Med J 313 (1996) 1512-1516
6. Hegi M.E., Diserens A.-C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003